Gabitril

Gabitril is a brand name of tiagabine, approved by the FDA in the following formulation(s):

GABITRIL (tiagabine hydrochloride - tablet; oral)

• 
  Manufacturer: CEPHALON
  
  Approval date: September 30, 1997
  
  Strength(s): 12MG, 16MG, 4MG ^[RLD][AB]


• 
  Manufacturer: CEPHALON
  
  Approval date: April 16, 1999
  
  Strength(s): 2MG ^[AB]

Has a generic version of Gabitril been approved?

A generic version of Gabitril has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Gabitril and have been approved by the FDA:

tiagabine hydrochloride tablet; oral

• 
  Manufacturer: SUN PHARM INDS
  
  Approval date: November 4, 2011
  
  Strength(s): 2MG ^[AB], 4MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gabitril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  N-(butenyl substituted) azaheterocyclic carboxylic acids
  Patent 5,010,090
  Issued: April 23, 1991
  Inventor(s): Gronvald; Frederik C. & Braestrup; Claus
  Assignee(s): Novo Nordisk A/S.
  1-Aminobut-3-en derivatives having optionally substituted furanyl, thienyl, pyridyl and/or pyrrolyl in the 4-position and 3-carboxypiperidin-1-yl, 3-carboxytetrahydropyrid-1-yl or 3 carboxymethylpyrrolidin-1-yl in the 1-position potentiate GABA-ergic neurotransmission.
  
  Patent expiration dates:
  
  
  • September 30, 2011
    
  
  



• 
  Crystalline Tiagabine monohydrate, its preparation and use
  Patent 5,354,760
  Issued: October 11, 1994
  Inventor(s): Petersen; Henning & Nielsen; Peter & Cain; Michael & Patel; Subhash
  Assignee(s): Novo Nordisk A/S
  The invention provides crystalline Tiagabine hydrochloride monohydrate, process for its preparation, compositions containing the same and its therapeutic use as anti-epileptic agent.
  
  Patent expiration dates:
  
  
  • March 24, 2012
    
  
  



• 
  Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
  Patent 5,866,590
  Issued: February 2, 1999
  Inventor(s): Svensson; J.o slashed.rgen Ryhl & Nygaard; Lars & Andersen; Tina Meinertz & Weibel; Helle & Hjorth; Thyge Borup
  Assignee(s): Novo Nordisk A/S
  The present invention provides a new stable pharmaceutical composition containing tiagabine hydrochloride as active ingredient.
  
  Patent expiration dates:
  
  
  • April 29, 2016
    
  
  



• 
  Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
  Patent 5,958,951
  Issued: September 28, 1999
  Inventor(s): Ahrndt; Preben & Petersen; Henning B.o slashed.rge & Chang; Vincent H. & Allen; Kimberly Ann & Cain; Michael H.
  Assignee(s): Novo Nordiskials
  The present invention provides R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride in its pure and stable anhydrous form.
  
  Patent expiration dates:
  
  
  • June 10, 2017
    
  
  

See also...

• Gabitril Consumer Information (Wolters Kluwer)
• Gabitril Consumer Information (Cerner Multum)
• Gabitril Advanced Consumer Information (Micromedex)
• Gabitril AHFS DI Monographs (ASHP)
• Tiagabine Consumer Information (Wolters Kluwer)
• Tiagabine Consumer Information (Cerner Multum)
• Tiagabine Advanced Consumer Information (Micromedex)
• Tiagabine Hydrochloride AHFS DI Monographs (ASHP)